Jennie H. Best, Ph.D.
Affiliations: | 2007 | University of Washington, Seattle, Seattle, WA |
Area:
Health Care ManagementGoogle:
"Jennie Best"Parents
Sign in to add mentor| David L. Veenstra | grad student | 2007 | University of Washington | |
| (Preference values for health states associated with colon cancer and its treatment.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pappas DA, Etzel CJ, Crabtree M, et al. (2020) Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry. The Journal of Rheumatology |
| Best JH, Vlad SC, Pei J. (2020) Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. Rheumatology and Therapy |
| Pappas DA, Blachley T, Best JH, et al. (2020) Fri0104 Persistence Of Tocilizumab Therapy Among Patients With Rheumatoid Arthritis: Data From The Us-Based Corrona Rheumatoid Arthritis Registry Annals of the Rheumatic Diseases. 79: 627-628 |
| Unizony S, Dang J, Han J, et al. (2020) Sat0125 Association Between Change In Health Assessment Questionnaire Disability Index And Treatment Response In Patients With Rheumatoid Arthritis In Tocilizumab Clinical Trials Annals of the Rheumatic Diseases. 79: 998-998 |
| Pappas DA, Blachley T, Zlotnick S, et al. (2020) Sat0118 Comparative Effectiveness Of Tocilizumab In Combination With Methotrexate Versus Tumor Necrosis Factor Inhibitors (Tnfis) In Combination With Methotrexate In Patients With Rheumatoid Arthritis With Prior Exposure To Tnfis Annals of the Rheumatic Diseases. 79: 993-993 |
| Pappas DA, Blachley T, Best JH, et al. (2020) Thu0177 Durability Of Response Among Patients With Rheumatoid Arthritis Initiating Tocilizumab: Data From The Us-Based Corrona Rheumatoid Arthritis Registry Annals of the Rheumatic Diseases. 79: 305-306 |
| Dang J, Uyei J, Jiang Y, et al. (2020) Ab0275 Comparative Efficacy (Das 28) Of Tocilizumab And Other Targeted Immune Modulators (Tims) For Rheumatoid Arthritis: A Network Meta-Analysis (Nma) Annals of the Rheumatic Diseases. 79: 1436-1437 |
| Best JH, Kong AM, Smith DM, et al. (2019) Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis. Clinicoeconomics and Outcomes Research : Ceor. 11: 799-807 |
| Best JH, Kong AM, Unizony S, et al. (2019) Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database. Rheumatology and Therapy |
| Pappas DA, Blachley T, Zlotnick S, et al. (2019) Sat0156 Methotrexate Discontinuation And Dose Decreases After Therapy With Tocilizumab: Results From The Corrona Rheumatoid Arthritis Registry Annals of the Rheumatic Diseases |